Hoertel: Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe Disease [Paxlovid]

Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe Disease

Hoertel et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2022.42140

Hoertel et al., Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk.., JAMA Network Open, doi:10.1001/jamanetworkopen.2022.42140

Nov 2022 Source PDF

Twitter
Facebook

All Studies Meta

Retrospective 62,525 hospitalized COVID-19 patients in France, showing that over 50% of patients that died had a contraindication for the use of Paxlovid. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy.

Important missing comments or errors? Let us know.

Hoertel et al., 15 Nov 2022, France, peer-reviewed, 5 authors, study period 24 January, 2020 - 30 November, 2021.

All Studies All Outcomes Submit Updates or Corrections

This Paper Paxlovid All

Abstract: Research Letter | Global Health Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe Disease Nicolas Hoertel, MD, MPH, PhD; David R. Boulware, MD, MPH; Marina Sánchez-Rico, MD, PhD; Anita Burgun, PhD; Frédéric Limosin, PhD

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit